Authorization

DiaSorin Obtains FDA Emergency Use Authorization and BARDA Funding for SARS-CoV-2 IgG Serology Kit for COVID-19 Testing in the U.S.

SALUGGIA, Italy, April 25, 2020 /PRNewswire/ --A DiaSorin (FTSE MIB: DIA) announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for the LIAISON SARS-CoV-2 S1/S2 IgG test.
DiaSorin Obtains FDA Emergency Use Authorization and BARDA Funding for SARS-CoV-2 IgG Serology Kit for COVID-19 Testing in the U.S.
The product is one of the first high-throughput assays based on the CLIA (Chemiluminescent ImmunoAssay) technology to receive EUA in the U.S.DiaSorin recently signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services to obtain funding aimed at making the test available in the U.S."Widely distributed tests are needed immediately to quickly identify not only people who have an active infection but also those who have recovered,"A said BARDA Acting Director Gary Disbrow, Ph.D.A "This knowledge is particularly important for healthcare providers and other critical infrastructure personnel, to return to work afterA anypotential exposure to SARS-CoV-2."
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2021    »
ПнВтСрЧтПтСбВс
1234567
891011121314
15161718192021
22232425262728